Paul Banwell to lead study on benefits of MitoQ supplements in skin cancer patients

New plans to investigate the effects ofnext-generation antioxidants in skincancer patients have been revealed. The pioneering study will be led byskincare specialist and consultantplastic surgeon Mr Paul Banwell fromThe Banwell Clinic at the McIndoeSurgical Centre, West Sussex.

Developed by two leading scientists,MitoQ antioxidant oral supplementshave been carefully formulated to acton the mitochondria in cells to enhanceand replace the body’s antioxidantdefence mechanisms. MitoQ uses anext-generation technology that isscientifically proven to deliver CoQ tocellular mitochondria at levels nearly1,000 times greater than existing CoQformulations. MrBanwell already recommendsMitoQ supplements to his skin cancer patients, based upon thescientific literature, but is nowtaking these concepts further bymeasuring oxidative stress levelsover time in skin cancer patients viahair and blood samples.

“Not all antioxidants are createdequal”, he said. “We selected MitoQ oralsupplements for these investigationsbecause it is a high grade antioxidant,which has been shown to be many timesmore powerful than other formulas. Using the most powerful antioxidantavailable gives this study the bestpossible chance of success. “We are keen to explore every avenueto help treat and prevent skin cancer. The scientific literature stronglysuggests that UV-mediated free radicaldamage is the main contributor to skincancer formation (and ageing) and weare therefore excited about exploringtargeted therapy with MitoQ.”